메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

논문 기본 정보

자료유형
학술저널
저자정보
류예리 (국립경상대학교)
저널정보
한양법학회 한양법학 한양법학 제26권 제2집 통권 제50집
발행연도
2015.5
수록면
25 - 42 (18page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
Korea-China FTA was finally concluded. It is expected that pharmaceuticals will increase to enter China’s market by the effect of tariff lowering, however, the problem is non-tariff barriers. Non-tariff barriers in the area of pharmaceuticals are included that CFDA accepts only the Chinese pharmacopoeia and applies the Chinese GMP, high standards of clinical test and so on. Abolition of non-tariff barriers such as shortening licensing period, simplifying procedures will bring effect of developing new drugs and increasing export to China.
The government needs to demand legitimacy of China’s unique standards for imported drugs, and some times bring forward their unreasonableness. And it is also recommended that we form a consultative group or body to negotiate to resolve implementation. Such a consultative group or body is working-level hot-line not just high level to suggest prompt remedies when disputes are happened.
The majority of notifications to the WTO TBT was in the area of food and drugs, especially requirements of cosmetics producers and labelling in 2012. After entering WTO, China has legislated and amended technical regulation to implement WTO agreement. During 2008-2009, every year around 200 notifications reached to the WTO, currently the number is stable, but still in ranking 10. Globally among notifications in 2012, food and drugs took the position of top, around 31.4%.
Therefore, the government instead of our enterprises should have an active plan for negotiating with the Chinese authority for resolving China’s technical regulations and, for that, designate(form) TBT task force. The TBT task force should focus on analyzing China’s technical regulations, enlarging support small and medium sized companies, and resolving the barriers.

목차

Ⅰ. 서론
Ⅱ. 중국 의약품분야 비관세장벽 현황 및 유형
Ⅲ. 중국 의약품분야 무역기술장벽의 WTO TBT협정 충돌성
Ⅳ. 한-중 FTA를 통한 중국의 무역기술장벽 대응방안
Ⅴ. 결론
참고문헌
Abstract

참고문헌 (16)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

이 논문과 함께 이용한 논문

최근 본 자료

전체보기

댓글(0)

0

UCI(KEPA) : I410-ECN-0101-2016-360-001757042